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Abstract
Background: Solutions for Wellness (SfW) is an educational 3-month program concerning nutrition and exercise for 
persons with psychiatric disorders on psychotropic medication, who have weight problems. This observational study 
assessed the impact of SfW on subjective well-being, weight and waist circumference (WC).
Methods: Data was collected at 49 psychiatric clinics. Where the SfW program was offered patients could enter the 
intervention group; where not, the control group. Subjective well-being was measured by the Subjective Well-being 
under Neuroleptics scale (SWN), at baseline, at the end of SfW participation, and at a follow-up 6 months after baseline. 
Demographic, disease and treatment data was also collected.
Results: 314 patients enrolled in the SfW group, 59 in the control group. 54% of the patients had schizophrenia, 67% 
received atypical antipsychotics, 56% were female. They averaged 41 ± 12.06 years and had a BMI of 31.4 ± 6.35. There 
were significant differences at baseline between groups for weight, SWN total score and other factors. Stepwise logistic 
models controlling for baseline covariates yielded an adjusted non-significant association between SfW program 
participation and response in subjective well-being (SWN increase). However, statistically significant associations were 
found between program participation and weight-response (weight loss or gain < 1 kg) OR = 2; 95% CI [1.1; 3.7] and 
between program participation and WC-response (WC decrease or increase < 2 cm) OR = 5; 95% CI [2.4; 10.3]), at 3 
months after baseline.
Conclusions: SfW program participation was associated with maintaining or decreasing weight and WC but not with 
improved subjective well-being as measured with the SWN scale.
Background
Weight gain and consequent obesity is a serious and
growing health problem, associated with an increased
risk of a number of somatic illnesses, e.g., type II diabetes
and cardiovascular disorders and with a reduction in
quality of life [1-3]. Persons with schizophrenia are even
more prone to weight gain and obesity than the general
population; possible reasons for this include change in
caloric intake and physical inactivity [4]. In addition to
this, weight gain is an adverse effect associated with many
antipsychotics, antidepressants and mood stabilizers [4-
8].
Several studies have investigated whether behavioral
interventions can be effective in curbing the weight gain
induced by psychotropic medication [9-24]. The inter-
vention programs evaluated in these studies ranged from
comprehensive group programs with motivational coun-
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seling, physical exercises and teaching healthy eating or
with cognitive therapy focusing on cognition in relation
to food and body weight to educational mailings about
the importance of diet and exercise. The designs of the
studies were diverse, encompassing single-arm observa-
tional studies, studies with matched controls and ran-
domized controlled trials. In the recent years, a few
reviews of studies of behavioural weight management in
persons with serious mental illness have been made [25-
28]. These reviews concurrently conclude that it is possi-
ble to manage weight gain in persons with serious mental
illness by means of behavioral interventions.
Only a few of the studies mentioned above took the
next step and included evaluation of the impact of behav-
ioural weight management on the quality of life (QoL) or
subjective well-being of the participants. In one random-
ized trial, a one-on-one nutrition education program was
found to increase QoL and reduce weight gain [18].
Another randomized trial evaluating an individual pro-
gram focusing on diet and exercise found that the persons
attending the program reduced the weight more than the
controls, but no difference was found between the groups
for QoL [10]. A third randomized trial evaluated a group
program comprising diet and physical activity [24]. This
program was also found to reduce weight, but QoL was
not improved. A single-arm study found decreased
weight and improved QoL after a group program com-
prising teaching healthy lifestyles as well as physical exer-
cise [9].
The Solutions for Wellness (SfW) educational program
in Scandinavia (Denmark, Norway and Sweden) is a well-
established 12-week group program for persons who suf-
fer from psychiatric disorders, use psychotropic medica-
tions and have weight problems. The program focuses on
working towards a healthier lifestyle, with two main ele-
ments: healthier diet and increased physical activity. The
primary objective of the observational study presented
here was to investigate the impact of the Scandinavian
SfW educational program on the development of subjec-
tive well-being and QoL as measured by changes in the
Subjective Well-Being under Neuroleptics (SWN) scale.
The population studied was suffering from chronic psy-
chiatric illness and treated by any psychotropic medica-
tion. Secondary objectives included to assess if potential
changes in subjective well-being and QoL during the pro-
gram were maintained at a follow-up 3 months after the
program ended, to describe the association between par-
ticipants' characteristics at baseline and SWN changes
during the program and 3 months later, and finally to
describe development in weight, BMI and waist circum-
ference after completion of the program and 3 months
later, as well as potential associations with baseline vari-
ables.
Methods
Study design
This observational study was carried out at 49 sites, 42
Solutions for Wellness (SfW) sites and 7 control sites,
located in Denmark, Norway and Sweden from 9-Aug-
2006 to 28-Feb-2008. The SfW sites included psychiatric
departments and clinics where the SfW program was well
established in normal clinical practice. Persons about to
enter the program were invited to enroll in the study. The
control sites were recruited among psychiatric depart-
ments and clinics that had not initiated the SfW program
yet. The control sites invited persons, who met the study
eligibility criteria, to enroll in the study as the control
group.
Eligible persons were either outpatients or inpatients in
non-acute wards (i.e., patients whose condition was rela-
tively stable). Criteria for enrollment included having a
psychiatric diagnosis and being on psychotropic medica-
tion, defined as antipsychotics, antidepressants or mood
stabilizers. They should also have a weight problem
(being overweight or gaining weight) in their personal
opinion and in the judgment of their healthcare provider,
but should not be on any pharmacologic intervention for
weight gain. Ethical review boards and regulatory author-
ities' approval were obtained in compliance with local
laws, and a written informed consent was given by each
person before entering the study.
The study consisted of 3 visits, where the baseline visit
was equivalent to the first lesson of the SfW program.
The endpoint visit occurred 3 months after baseline and
was equivalent to the last lesson or lesson 12 in case the
program was longer than 12 weeks. The follow-up visit
took place 6 months after baseline, i.e., 3 months after the
SfW program completion. The control group participants
only had two data collection points, baseline and end-
point (3 months apart). Decisions on the treatment and
care were made by the healthcare providers according to
normal clinical practice, and collected data reflect real-
life practice.
Solutions for Wellness educational program
"Solutions for Wellness" has different meanings in differ-
ent countries. In Scandinavia, SfW is a standardized pro-
gram, which is performed in a group setting in
psychiatric departments and clinics under the guidance
of specially trained nurses or therapists. The specially
trained nurses or therapists are health care professionals
who have their daily work in the participating depart-
ments and clinics, and who have been trained by the
same, few SfW project managers, individually and in
group trainings. The SfW program in Scandinavia usually
consists of 12 lessons that focus on nutrition/eating hab-
its or physical activity or both of these subjects. The les-Porsdal et al. BMC Psychiatry 2010, 10:42
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sons are based on written material (manuals for patients
and program coordinators). The written material covers
18 subjects related to eating and 14 subjects related to
physical activity, and the nurses and therapists select and
combine these subjects according to the needs of the pro-
gram participants. The lessons are given to small groups
of patients (often 4-8), who will go through the program
together, typically with one lesson per week.
Assessment of outcome
At each visit, weight and waist circumference were mea-
sured and the participants assessed their subjective well-
being by answering the questions in the Subjective Well-
being under Neuroleptics scale (SWN) [29,30] and with a
generic QoL instrument, 15D [31]. The investigators
rated the Clinical Global Impression of severity (CGI-S)
at all visits [32]. Participants were weighed at the same
time of the day on the same scale without wearing shoes.
Waist circumference was measured between the lowest
rib margin and the iliac crest. All study procedures,
except for the self-assessed 15D QoL questionnaire and
the investigators' assessment of CGI-S, were integrated
parts of the SfW program.
Information on demographics (age, sex and height),
medical history (diagnosis, duration of illness) and psy-
chotropic medication at entry into the program was col-
lected at the baseline visit. Number of SfW lessons
attended was registered at the endpoint visit.
Health outcome/quality of life measures
The Subjective Well-Being under Neuroleptics (SWN)
is a self-rating scale constructed by Naber and coworkers,
[29,33] with the underlying assumption that subjective
well-being is a major determinant of medication compli-
ance in schizophrenia. Neuroleptic drugs differ with
respect to their tendency to produce side effects, and the
SWN scale was developed to cover such differences in
side effects, resulting in five subscales: Mental function-
ing, Social integration, Emotional regulation, Physical
functioning and Self-control. The SWN scale is only
moderately correlated to objective psychopathology as
assessed with the positive and negative syndrome scale
(PANSS) and to the established Udvalg for kliniske
undersøgelser (UKU) side effect scale [30,34]. The origi-
nal SWN scale consists of 38 items and has been used in
several international trials [30]. In order to improve the
utility of the instrument, a short form was developed,
consisting of 20 items with four items covering each of
the five dimensions. The short form has good psycho-
metric properties [30,35] and it was used in the present
study. Items are scored on a 1 - 6 scale, where 1 is indicat-
ing "not at all" and 6 is indicating "very much". Total score
and subscales scores were computed.
The  15D Quality of Life instrument is a generic
health-related QoL instrument that, due to its simplicity
and easy applicability, can always be included in health
program evaluation studies [31]. The 15D covers 15
items, namely: mobility, vision, hearing, breathing, sleep-
ing, eating, speech, elimination, usual activities, mental
function, discomfort and symptoms, depression, distress,
vitality and sexual activity. Each item comprises one
question with five answer options. A single index score
on a 0-1 scale (0 = being dead, 1 = full health) is com-
puted. The 15D has been used in projects evaluating
medical interventions and rehabilitation and in National
Health surveys in Finland and Denmark. Based on empir-
ical research, a change of 0.02-0.03 on the single index
score of 15D is considered clinically relevant [31].
The Clinical Global Impression - Severity (CGI-S) is
a single-item clinician rating of the severity of the per-
son's psychiatric symptoms in relation to the clinician's
total experience of previous persons with the same diag-
nosis [32]. Severity is rated on a seven-point Likert scale
(1 = normal, not ill at all, 7 = among the most extremely ill
patients).
Determination of sample size
The primary objective of this study was to describe the
participants' change in subjective well-being, as mea-
sured by the SWN, at the end of the three-month period
for the SfW group compared to the control group. No
clinically meaningful change has been defined for the
SWN scale before, and it was decided to use a between-
group difference in the proportion of participants with
any SWN improvement for the sample size calculation.
The sample size was estimated based on the following
assumptions and settings: an expected proportion of par-
ticipants with any SWN improvement of 50% in the con-
trol group and of 70% in the SfW group, a power of 80%
to detect such a difference and a two-sided significance
level of 0.05. Enrollment of 300 participants was planned
for the SfW group and 55 participants for the control
group, and enrollment ended when baseline and end-
point observations had been registered from these num-
bers of persons.
Statistical analysis
Analyses were conducted in the full analysis set (all
enrolled persons). Missing data were not replaced, for
each SWN-subscale, a missing answer to any item yielded
a missing sub-score and, therefore a missing total score.
All baseline characteristics were summarized using stan-
dard descriptive statistics by study group (SfW/control)
and, for diagnosis-related baseline data (collected at visit
1), by diagnosis. Baseline variables were compared
between groups by means of the chi-square or the Fisher-Porsdal et al. BMC Psychiatry 2010, 10:42
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Freeman-Halton exact test for categorical variables, and
the t-test in case of continuous variables. Changes over
time within each group were tested by means of the
paired t-test.
The primary analysis tested the between-group differ-
ence on the rate of responses in terms of subjective well-
being at completion of the program (percentage of sub-
jects who experienced an improvement, i.e. SWN
increase after 3 months), using the Chi-square test. The
response rates at month 3 were estimated in the SfW and
control groups, as well as their between-group difference
and 95% confidence intervals (exacts). At month 3, step-
wise logistic regression models were fit to assess the SfW
association with subjective well-being. A logit-link func-
tion was chosen to relate the dichotomous response vari-
able of improving subjective well-being adjusting for the
following baseline variables: gender, age, psychiatric diag-
nosis (bipolar, schizophrenia, other), duration of illness,
and symptom severity (CGI-S scale), SWN score, waist
measurement, weight, BMI and psychotropic drugs. The
significance level for entry in the model was 0.10 and 0.05
for remaining in the model. First degree interactions
between main effects still present were tested through a
second stepwise process using the same significance lev-
els as above. The group variable was forced in the model
and maintained even if not significant. One-by-one inter-
actions were fitted into the model as well and maintained
if significant.
As a measure of association between the response vari-
able and the independent variables, the odds ratios (ORs)
with the relative 95% confidence interval as well as the p-
value, were reported. For continuous variables, to provide
a useful interpretation, the estimated ORs were expressed
for a change of 1 unit in the covariate.
A similar analysis, conducted only in the SfW group,
was conducted on the response at month 6, replacing the
study group by the number of SfW lessons attended.
Crude mean changes from baseline to 3 months and 6
months, as well as from 3 months to 6 months, in SWN
scores/subscores, weight, BMI and waist circumference
were estimated along with their 95% confidence intervals.
A sensitivity analysis was conducted after implausible
waist circumference values were discovered lately in the
database (changes from 25 cm to 96 cm over 3 months) to
assess their impact on results (impossible values were set
to missing).
A post-hoc analysis was performed to further investi-
gate the response rates for weight, waist circumference
and CGI-Severity, as well as associated factors. For waist
circumference a decrease was defined as a decrease of at
least 2 cm, a stable waist circumference was defined as a
change between - 2 cm and 2 cm, and an increase was
defined as 2 cm increase or more. For weight a decrease
was defined as a loss of at least 1 kg, stable weight was a
change between - 1 and 1 kg, and an increase was a gain
of at least 1 kg. For waist circumference and weight the
response was defined as a decrease or stable waist cir-
cumference or weight, as described above. For CGI-S, the
response was defined as a decrease. All analyses were
computed using SAS®9, SAS Institute Inc., SAS Campus
Drive, Cary, North Carolina 27513, USA.
Results
Participant characteristics
In total, 373 participants were enrolled in the study, of
which 314 were in the SfW group and 59 in the control
group, meaning that they had both the baseline and the 3
months visits (Figure 1). A total of 278 (89%) of the SfW
group participants had a 6 months visit. No 6 months
visit was planned for the control group.
Table 1 describes the baseline characteristics. There
were statistically significant differences between groups
for weight, BMI, SWN total score, 15D and CGI-S total
score. A large number of the enrolled persons suffered
from schizophrenia, a lesser number from bipolar disor-
der and other psychiatric diagnoses. More participants in
the SfW group had other psychiatric disorders than
schizophrenia and bipolar disorder, compared with the
control group. The majority of the participants were
treated with atypical antipsychotics or antidepressants.
Antidepressant medication was about twice as prevalent
in the SfW group as in the control group. The mean num-
ber of lessons attended by the SfW group was 9.8 (stan-
dard deviation: 3.5). A total of 215 (69%) of the SfW
participants had 9 or more lessons, 80 (26%) had at least
12 lessons and 9% were registered to have had more than
12. Repeating lessons is allowed in the SfW program.
Impact of the SfW program on subjective well-being and 
factors associated with response
The rate of participants that had a response (increased
score) in the SWN total score at 3 months from baseline
was 60.1% for the SfW group and 57.9% for the control
group. The between-group difference was 2.2% (95% CI: -
Figure 1 Participant flow.Porsdal et al. BMC Psychiatry 2010, 10:42
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Table 1: Person demographics and illness characteristics at baseline
Person Characteristics SfW N = 314 Control N = 59 P-Values
Female patients, n (%) 180 (57.3) 30 (50.8) 0.3574
Agea, yrs, (± SD) 41.2 (± 11.97) 39.9 (± 12.55) 0.4532
Weighta, kg, (± SD) 93.5 (± 20.88) 87.6 (± 18.53) 0.0437*
Heighta, cm, (± SD) 171.6 (± 9.43) 171.8 (± 9.35) 0.8765
BMIa, kg/m2, (± SD) 31.7 (± 6.48) 29.6 (± 5.33) 0.0173*
Waist circumferencea, cm, (± SD) 107.5(± 18.52) 105.9 (± 18.90) 0.5544
Waist circumference Sensitivity 
analysisa, cm (± SD)
106.4 (± 16.37) 103.5(± 13.89) 0.2115
15D total score a, (± SD) 0.814 (± 0.12) 0.857(± 0.09) 0.0085*
SWN total score a, (± SD) 80.5 (± 15.97 87.9 (± 18.35) 0.0016*
Clinical Characteristics
Psychiatric Diagnosis 0.0627
Schizophrenia n (%) 163 (51.9) 40 (67.8)
Bipolar Disorder n (%) 28 (8.9) 5 (8.5)
Other n (%) 123 (39.2) 14 (23.7)
Time since diagnosisa, b, yrs, (± SD) 9.47 (9.68) 11.36 (12.27) 0.1911
CGI-S total scorea, (± SD) 4.1 (± 0.99) 3.4 (± 1.59) < 0.0001
Psychotropic medication
Atypical antipsychotics n (%) c 203 (64.6) 46 (78.0)
Antidepressants n (%) 124 (39.5) 12 (20.3)
Typical Antipsychotics n (%) 70 (22.3) 14 (23.7)
* = Significant differences between groups a = mean values, SWN = Subjective Well-being under Neuroleptics Scale, SfW = Solutions for 
Wellness group, 15D = 15 dimensions quality of life instrument, bN patients = 307 and 59 respectively The most common atypical 
antipsychotic drugs in the SfW group were olanzapine and risperidone (17% of the patients each), and in the control group the most common 
atypical antipsychotics were olanzapine and quetiapine (25% and 20% each).Porsdal et al. BMC Psychiatry 2010, 10:42
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11.8; 16.2). From baseline to 6 months, the response rate
for the SfW group was 65.5%. After adjustment for poten-
tial baseline confounders, participation in the SfW pro-
gram had no statistically significant impact on response
in the initial or sensitivity analysis, neither at Month 3
nor 6 (Table 2). At Months 3 and 6, only the SWN score at
baseline was significantly associated with the outcome
(lower scores with better outcome), both in initial and
sensitivity analysis.
SWN total score mean change throughout the study
The mean change in SWN total score between baseline
and 3 months for the SfW group was +3.3 (95% CI: 1.9;
4.7) and for the control group +1.9 (95% CI: -1.2; 4.9). The
mean change from 3 months to 6 months was an increase
by +1.4 (95% CI: 0; 2.7) for the SfW group.
SWN subscales: response rates per visit and factors 
associated with response
In the initial crude analysis, there were statistically signif-
icant differences between the SfW group and the control
group for two of the five subscales, namely emotional reg-
ulation and social integration. After adjusting for baseline
covariates and interactions, only the emotional regulation
subscale still had a significantly better response rate for
SfW participants compared to the control group partici-
pants (and this only in the sensitivity analysis) with an
odds ratio (OR) of 2.00 (95% CI: 1.05; 3.80).
Other factors associated with response for SWN sub-
scales were the SWN subscale scores at baseline, where
lower scores at baseline were associated with a higher
chance for response, for all subscales, at both 3 and 6
months, in both initial and sensitivity analysis. These ORs
were all in the interval between 0.79 and 0.86 (95% CIs all
in the interval between 0.73 and 0.92). For self-control,
the duration of illness (measured in years) seemed to have
an impact on chance for response at 3 months with OR of
0.97 (95% CI: 0.95; 1.00), there was no difference at 6
months. For physical functioning, higher age (OR: 1.03
[95% CI: 1.01; 1.06]) and shorter duration of illness (OR:
0.95 [95% CI: 0.93; 0.98]) were associated with a higher
chance for response at 3 months, but there was no differ-
ence at 6 months. For the social integration subscale,
higher age was associated with a higher chance for
response at 3 months (OR: 1.02 (95% CI: 1.00; 1.04)), but
not at 6 months. For social integration, diagnosis (schizo-
phrenia) was found to be a significant factor at month 3
in the initial analysis, but not in the sensitivity analysis,
and lower baseline waist circumference seemed slightly
associated with an improvement at Month 6, but this was
not confirmed by the sensitivity analysis.
15D Total score: mean changes throughout study and 
correlation with SWN scale
From baseline to 3 months the SfW group showed a mean
change in the 15D score of 0.023 (95% CI: 0.013; 0.033)
and the control group had a mean change of 0.001 (95%
CI: -0.016; 0.019). Between 3 months and 6 months the
SfW group had a 15D change of 0.002 (95% CI: -0.007;
0.012).
There was a fair degree of concordance between the
SWN (total) and the 15D scale: correlations from 0.60 to
0.79.
Weight changes and associated factors
The mean change in weight from baseline to 3 months
was -0.5 kg (95% CI: -0.9;-0.2) for the SfW group and 0.9
kg (95% CI: 0; 1.8) for the control group. Between Month
3 and Month 6, the mean weight of the SfW group
decreased by another 0.2 kg (95% CI: -0.6; 0.3).
From baseline to 3 months, 38% had a decrease of their
weight, 36% had a stable weight and 26% had an increase
of the weight in the SfW group. The corresponding fig-
ures for the control group were 26%, 33% and 40% (Figure
2).
Response rates from baseline to 3 months were 74% for
SfW participants and 60% for control group participants.
From baseline to 6 months, 46% had a decrease of the
weight, 23% had a stable weight, and 31% increased their
weight, in the SfW group.
Factors associated with better response at 3 months
included participation in the SfW program, older age and
being treated in Denmark (Table 3). At 6 months, high
Table 2: Baseline factors associated with SWN response (ORs and CI)
Factor Month 3 Month 6
Initial analysis Sensitivity analysis Initial analysis Sensitivity analysis
Baseline SWN 0.976 [0.963;0.990] 0.977 [0.963;0.991] 0.963 [0.945;0.980] 0.960 [0.942;0.978]
SfW versus no SfW 0.914 [0.500;1.671] 0.951 [0.516;1.753] - -
# Attended Lessons - - 0.990 [0.911;1.075] 0.991 [0.911;1.078]
-: not included in the logistic modelsPorsdal et al. BMC Psychiatry 2010, 10:42
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baseline SWN scores and living in Denmark or Sweden
were found significant.
None of the factors diagnosis, duration of illness, psy-
chotropic drug at baseline, sex, weight or CGI at baseline
had any effect.
Waist circumference changes and associated factors
In the initial analysis, both the SfW and the control group
decreased in waist circumference (WC) between baseline
and 3 months, but in the sensitivity analysis the SfW
group was observed to have a decrease of the mean waist
circumference of 2.2 cm (95% CI: -2.8; -1.6) while the
control group had an increase of 1.2 cm (95% CI: 0; 2.4).
Between 3 and 6 months, the mean change of the waist
circumference was close to zero for the SfW group: -0.1
cm (95% CI: -0.6; 0.5).
The rates for decreased, stable and increased waist cir-
cumference were 48%, 37% and 16% for the SfW group
and 19%, 44% and 37% for the control group from base-
line to 3 months (Figure 3).
Response rates from baseline to 3 months were 84% for
SfW participants and 63% for control group participants.
From baseline to 6 months, 47% of participants in the
SfW group had a decrease of their waist circumference,
34% were stable, and 19% had an increase.
Factors associated with response at 3 months were
found to be participation in the SfW program, being in
Denmark or Sweden and having a high baseline waist cir-
cumference (Table 3). A significant interaction between
the latter characteristic and BMI made this impact
weaker when associated with a high BMI.
At Month 6, participation in Denmark or Sweden and
having a high baseline waist circumference were found to
impact the response.
None of the factors age, sex, diagnosis and duration of
i l l n e s s ,  p s y c h o t r o p i c  d r u g  a t  b a s e l i n e ,  w e i g h t ,  C G I  o r
SWN at baseline had any effect.
CGI-S changes over time and associated factors
The mean change from baseline to 3 months was -0.4
(95% CI: -0.5; -0.3) for the SfW group and 0 (95% CI: -0.3;
0.2) for the control group.
The response rates for the SfW and control group from
baseline to 3 months were 37.3% and 28.1%. From 3 to 6
months the participants in the SfW group had a change in
CGI-S of 0.1 (95% CI: 0; 0.2).
Factors associated with a better response at 3 months
were a higher CGI-S at baseline (OR: 1.83, 95% CI: 1.45;
2.29) and a shorter time since diagnosis, in years, (OR:
0.96, 95% CI: 0.93; 0.98). Participation in the SfW pro-
gram, sex, age, diagnosis, psychotropic drug taken at
baseline, country, SWN total score, weight, BMI and
waist circumference at baseline did not impact the
chance of response.
Factors associated with response at 6 months in SfW
participants were: number of attended lessons (OR: 1.3,
95% CI: 1.18; 1.44) and an interaction between country
and baseline CGI-S (p = 0.021), though the effect of the
country alone (p = 0.0528) and CGI-S alone (p = 0.3472)
were hardly or not significant. The country effect seemed
to be driven by the difference Sweden vs. Denmark (p =
0.0289, OR = 0.017) rather than Norway vs. Denmark (p
= 0.8), suggesting poorer outcomes in Sweden compared
to Denmark and similar ones between Norway and Den-
mark. However, those effects are modified through the
interaction with CGI-S at baseline: higher CGI-S score
have a positive impact on response in Sweden vs. Den-
Figure 2 Weight categorical changes from baseline. SfW: Solutions for Wellness group.Porsdal et al. BMC Psychiatry 2010, 10:42
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mark (p = 0.0067, OR = 3.34), while none in Norway vs.
Denmark (p = 0.319, OR = 1.48).
Sex, age, diagnosis, time since diagnosis, psychotropic
drug taken at baseline, waist circumference, BMI, weight
and SWN total score at baseline did not have any effect.
Discussion
The SWN total score response rates for the period
between baseline and 3 months were not found to be sig-
nificantly different for participants who participated in
the SfW program and for participants in the control
group, neither in the primary analysis nor after control-
ling for differences in baseline variables. However, for one
of the SWN subscales, emotional regulation, OR for
response was almost 2 for SfW participants compared
with controls in the sensitivity analysis. The content of
the emotional regulation subscale is hope for the future,
intensity of emotions, interest in what is happening and
confidence. Participation in regular group activities for
the SfW group participants may have had a positive
impact on these aspects. For the other four SWN sub-
scales SfW participation was not associated with a higher
chance for improvement of the score.
T h e  o n l y  c l i n i c a l  f a c t o r  a s s o c i a t e d  c o n s i s t e n t l y  w i t h
improvement in SWN scores was the SWN score at base-
line (lower subjective well-being giving a higher probabil-
ity of improvement). Greater age of the person and
shorter duration of illness both were associated with
improved subjective well-being on two dimensions each
at 3 months: age on physical functioning and social inte-
gration and duration of illness on self-control and physi-
cal functioning. Diagnosis and symptom severity at
baseline were not found to play any role here.
The choice of the short-form of the SWN scale in this
study was governed by the history of the scale as it was
developed and validated in a clinical trial measuring the
subjective well-being of persons with schizophrenia [30],
and also because this scale was already part of the SfW
program in Scandinavia and the feedback from the SfW
instructors about the ability of the participants to fill in
the scale was positive.
Table 3: Baseline factors associated with weight and waist circumference response (ORs and CI)
Factor Weight Waist circumference
3 months 6 months 3 months 6 months
SfW versus no SfW 1.97 [1.06;3.68] - 4.96 [2.40;10.34] -
# Attended Lessons - n.s. - n.s.
Age (yrs) 1.04 [1.02;1.07] n.s. n.s. n.s.
Norway vs. Denmark 0.44 [0.28;0.85] 0.22
[0.10;0.44]
0.26
[0.12;057]
0.22
[0.09;0.52]
Sweden vs. Denmark 0.46 [0.25;0.86] n.s. n.s. n.s.
SWN total score at baseline n.s. 1.02
[1.002;1.04]
n.s. n.s.
Waist circumference at 
baseline (cm)
n.s. n.s. 1.185
[< .0001]a
1.03
[1.005;1.05]
BMI at baseline (kg/m2) n.s. n.s. 1.215
[0.0964]a
n.s.
Waist circ and BMI interaction 
at baseline (kg/m2)
n.s. n.s. 0.997
[0.0018]a
n.s.
a: Type 3 p-value - no confidence interval for OR is provided due to role in interaction
-: not included in the logistic modelsPorsdal et al. BMC Psychiatry 2010, 10:42
http://www.biomedcentral.com/1471-244X/10/42
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For the SfW group the mean change from baseline to
Month 3 in the SWN total score was +3.3 (95% CI: 1.9;
4.7) and from 3 months to 6 months the mean change was
+1.4 (95% CI: 0; 2.7). These changes on SWN score are
much smaller than what was reported in another study
[34]. That double-blind randomized clinical trial enrolled
114 persons with schizophrenia who changed from other
antipsychotics to olanzapine or clozapine. Of the 99 per-
sons who had a SWN score post-baseline, mean improve-
ments in SWN score at 26 weeks (+SD) were found to be
11.3 ± 20.7 points for olanzapine and 8.2 ± 15.8 points for
clozapine.
Reasons for observing these differences in change in
SWN score may be multiple. Part of the explanation of
the much smaller change in SWN score in this study may
be that only persons in psychiatric day care or outpatient
clinics and inpatients in non-acute wards were included,
i.e., relatively clinically stable patients. Only a total of 118
persons of the sample (32%) were markedly ill or more
severely affected as measured on the CGI-S scale, com-
pared with the clinical trial where the majority (84% to
93%) was at least markedly ill. Probably, the focus on sta-
ble persons in this study makes the evaluation of the
impact of participation in SfW on subjective well-being
more valid as the effect of other interventions as well as
clinical fluctuations over time are smaller for this group
than for more acute patients. Another aspect is that the
SWN scale, as mentioned, was developed for persons
with schizophrenia, and in this study, unlike the trial
mentioned above, 170 persons (46%) had another psychi-
atric disorder than schizophrenia, which means that this
scale may not have captured the improvement of all
almost half of the persons optimally. Still, the change in
QoL as measured with 15D was modest too and not sig-
nificantly different between the two groups either.
In several important respects, the SfW group differed
from the control group, as it had a significantly higher
baseline weight and BMI and lower QoL (15D) and sub-
jective well-being (SWN). Furthermore, the SfW group
was more severely ill (CGI-S) and contained almost twice
as many persons with "other" diagnoses compared to the
control group (39.2% vs. 23.7%). The fact that antidepres-
sants were about twice as common in the SfW group
(39.6% vs. 20.3%) indicates that depressed persons were
substantially more common in the SfW group. Persons
with depression may have more pronounced difficulties
finding the motivation necessary for any change in life-
style, both regarding diet changes or physical exercise
habits, which has possibly contributed to the modest
change in SWN score in the SfW group. Most of the
above mentioned differences between the two groups
w e r e  c o n t r o l l e d  f o r  i n  t h e  l o g i s t i c  r e g r e s s i o n  a n a l y s e s
(weight, BMI, SWN and CGI-S at baseline), but as diag-
noses were not collected for the persons who did not have
either schizophrenia or bipolar disorder (i.e. they were
categorized as "other") it was not possible to adjust fully
for the differences in diagnoses between SfW participants
and controls. The reason for the way diagnoses were reg-
istered in the study (schizophrenia/bipolar disorder/
other) is that the SfW program was started with persons
with schizophrenia in mind, and it was expected that
almost all participants would have schizophrenia (which
was also the reason for choosing the SWN scale as an
outcome measure). However, this study has shown that
the program is now used for a much more diverse popu-
lation. The differences in diagnoses between the two
groups is a limitation of this study (due to its non-ran-
domized design), and likewise, there may also be other
variables that influenced the outcome, which were not
equally distributed between the SfW participants and the
Figure 3 Waist circumference categorical changes from baseline. SfW: Solutions for Wellness group.Porsdal et al. BMC Psychiatry 2010, 10:42
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controls, and which were not measured, and which could
therefore not be controlled for in the statistical analysis.
Examples of such variables could be: previous weight
gain, eating disorders and treatment changes during or
after the program. These differences between the two
groups, both the ones that are known now and the ones
that may exist, but were not investigated as we wanted to
keep the study simple, illustrate the main limitation of
using a non-randomized design, which is the difficulty of
assessing the validity of differences found, or not found,
between the groups in terms of outcome of the interven-
tions.
As described, the control group consisted of persons
eligible for entering the SfW program but treated at hos-
pital departments and outpatient clinics which did not
run the SfW program. This design was chosen in order to
ensure a clear separation between the SfW group and the
control group in order to be able to investigate the rela-
tionship between participation in SfW and any observed
change. However, whereas the treatment of the psychiat-
ric disorders must be assumed to be comparable in cen-
ters running the SfW program and centers not running
the SfW program, it was out of our control if the centers
collecting participants for the control group had other
programs or activities with a similar effect on the well-
being as the SfW program. In theory, a better design
could be to run a cluster-randomized clinical trial, ran-
domizing departments and clinics to program participa-
tion or not, but at the time when it was decided to run
this study the SfW program was already established in
many settings in Scandinavia.
Alternative designs would have been to recruit persons
for the SfW group and for the control group in the same
departments and clinics, with or without randomization
to the two groups, so that the participants in the two
groups would be exposed to the same treatment of psy-
chiatric disorders and the same "other activities", but this
was found suboptimal as the care of the participants in
the control group would be influenced by the fact that the
program was run by the department, as the change in
knowledge and attitudes induced among the caregivers
through working with the program would have an impact
on all patients. Still, having decided to recruit SfW
patients and control patients in different departments, it
could have been possible to explore and describe the dif-
ferences between SfW centers and the control centers in
terms of what "other activities" they were running in
order to try to evaluate the possible impact of these, and
using matched controls instead of controls who "only"
were eligible for participation in the program could have
reduced the differences between the groups and
improved the validity of the results.
The country where the study participants were enrolled
was significantly associated with the probability of
response for both weight and waist circumference at both
time points: participants in Denmark had better chances
to stabilize their weight at Month 3, and having partici-
pated in the study in Denmark or Sweden was associated
with a better outcome for weight at Month 6 and for waist
circumference at both time points. The results presented
in this publication are mean results achieved across cen-
ters with different ways of implementing the SfW pro-
gram and working with lifestyle intervention in general.
The differences regarding weight and waist circumfer-
ence control between the three countries suggest that dif-
ferent approaches were developed at a country level. The
way the program was implemented was not registered as
part of the study, but differences between centers were
noticed: some centers focused on diet, others on physical
activity, some taught mainly theory, whereas others used
a more active and practical approach with for example
outdoor activities. The SfW as an educational program is
focusing on knowledge and attitudes. But it is not
increased knowledge that changes the weight, but
improved lifestyle habits. A more practical approach, per-
h a p s  l e a d i n g  t o  a  l a r g e r  d e g r e e  o f  c h a n g e  o f  b e h a v i o r
among the participants, might have generated a larger
mean weight loss. The differences in results between cen-
ters with different approaches have not been analyzed in
this piece of work, but would be an interesting next step
for a research project.
A number of other studies evaluated the impact on
weight of behavioural programs more or less similar to
the Scandinavian SfW program, and the results from
these studies are generally in line with the findings from
the study reported here with regards to development dur-
ing program participation [9-28]. Some of these studies
also followed the participants after program cessation to
evaluate the persistence of the effect on weight
[9,18,20,21], and these studies found, like the one
reported here, that the effect of the program seemed to
last in the period from the end of the program and up to
the end of follow-up a few months later. It is interesting to
see how the results from this study and many other stud-
ies match in this respect, and it is important to acknowl-
e d g e  t h a t  e v e n  t h o u g h  t h e  w e i g h t  l o s s  d u r i n g  S f W
program participation was not large, 0.5 kg, the persons
were referred to the SfW program because of gaining
weight or having weight problems, and while participat-
ing in the program 38% of the persons lost weight and
36% stayed stable. These, findings, all pointing in the
same direction, contrast with the results on subjective
well-being and QoL. Only a few studies included these
outcome measures, and among three randomized con-
trolled trials only one found a positive impact of thePorsdal et al. BMC Psychiatry 2010, 10:42
http://www.biomedcentral.com/1471-244X/10/42
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intervention on QoL [10,18,24]. However, all these stud-
ies had small sample sizes, and low statistical power may
have contributed to the lack of finding of positive changes
in QoL in the other two studies.
The SfW group was found to improve significantly
from baseline to Month 3 regarding the severity of the
psychiatric disorder as measured with CGI-S score,
whereas the control group did not change. When inter-
preting this finding it is relevant to take in consideration
that the study was an observational, open-label study, and
that bias may play a role for this difference between the
groups. Some centers made CGI-S ratings at clinical con-
ferences, where staff not working with SfW was also pres-
ent. This is a good practice in order to reduce the bias
introduced when investigators rate their own patients
and through that the quality of their own work. This
practice was, however, not implemented in all centers.
The statistical methods used illustrate the exploratory
nature of the study . No clinically meaningful difference
has been defined for the primary outcome measure, the
SWN scale, and it was decided to use a difference in the
proportion of participants with a SWN improvement
between the two groups of 70% - 50% or larger for the
sample size calculation. In order to reach a power of 80%,
with a two-sided type I error of 0.05, 300 persons were
enrolled in the treatment group and 55 persons in the
control group. Uneven treatment groups were chosen as
the widespread implementation of the SfW program
would have made recruitment of more SfW-naïve depart-
ments and clinics difficult.
Conclusion
In conclusion, the Solutions for Wellness program was
not shown to have a positive impact on the subjective
well-being of the participants relative to the control
group, as measured with the SWN scale, but Solution for
Wellness program participation was associated with
maintaining weight and waist circumference and the pro-
gram may allow health care professionals to help persons
under psychotropic treatment to control their weight.
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